Dealing With Drug-Resistant Prostate Cancer

by Julia Samuel on  December 29, 2017 at 2:09 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Prostate cancer is cured by surgical removal of a tumour and/or by radiotherapy. However, 20% of patients will need treatment to remove tumor cells but this treatment ceases to be effective after two or three years and cancer develops further.
Dealing With Drug-Resistant Prostate Cancer
Dealing With Drug-Resistant Prostate Cancer

Once this stage of the disease has been reached, there is no cure. A team headed by Xavier Salvatella, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), has discovered a new avenue through which to attack prostate cancer cells that have developed drug-resistance.

Show Full Article


A clear target and new sites of attack

The survival and proliferation of prostate tumor cells calls for highly active androgen receptor protein. The drug used to remove tumor cells interferes with this protein by binding to a specific region of the receptor and blocking its activity. "Over time, the protein accumulates alterations and mutates, and there comes a point where it is futile to target this region with drugs because, in fact, it is no longer there," says Salvatella.

The Molecular Biophysics Laboratory, headed by Salvatella, studies the tridimensional structure and atomic movements of the androgen receptor, with the aim to find new binding sites. It has been known for some years that the protein has a small region, spanning only 20 amino acids, that is important for tumor cell survival.

The study now describes for the first time that this region usually without a structure and therefore a priori disregarded as a drug target--has a helix shape. Upon gaining this helix--it is not known how the helix occurs, another protein, called TFIIF, binds to it. The study reveals that this interaction stimulates the activity of the androgen receptor and, consequently, facilitates the survival and multiplication of tumor cells.

To this 20-residue motif in the androgen receptor, the IRB Barcelona teams now add the protein TFIIF as a potential therapeutic target for prostate cancer. "The fact that TFIIF is a folded protein with a more defined structure makes it easier to search for drugs that can interfere with its interaction with the motif. For prostate tumor cells that have become resistant to treatment, we believe that this interaction could be their last mechanism through which to survive and proliferate," explains Salvatella.

"Using cells in vitro, we have seen that if we remove this region, the TFIIF protein can't bind to the androgen receptor. So if the interaction does not occur, the androgen receptor loses activity, which is what we are interested in achieving," says Elzbieta Maria Szulc.

In collaboration with experts in computational modeling, the scientists are searching for drugs that interfere with TFIIF. "We don't know whether such drugs will have a positive effect on cells, but the data available is promising," says Salvatella.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive